Quinoline is a hepatocarcinogen in rats and mice and a well-known mutagen in bacteria after incubation with rat liver microsomes. The specific cytochrome P450 enzymes involved in quinoline metabolism in human and rat liver microsomes were determined using cDNA-expressed cytochrome P450s, correlations with specific cytochrome P450-linked monooxygenase activities in human liver microsomes and inhibition by specific inhibitors and antibodies. CYP2A6 is the principal cytochrome P450 involved in the formation of quinoline-1-oxide in human liver microsomes (correlation coefficient r = 0.95), but is formed in only minute quantities in rat liver microsomes. CYP2E1 is the principal cytochrome P450 involved in the formation of 3-hydroxyquinoline (r = 0.93) in human liver microsomes and is involved in the formation in rat liver microsomes. A high correlation coefficient (r = 0.91) between CYP2A6 activity and quinoline-5,6-diol formation in human liver microsomes was observed, but this most likely reflects the involvement of CYP2A6 in the formation of quinoline-5,6-epoxide, from which the quinoline-5,6-diol is formed, as conversion of quinoline-5,6-epoxide to quinoline-5,6-diol on incubation of the epoxide with CYP2A6 could not be demonstrated. A cDNA-expressed human microsomal epoxide hydrolase, however, efficiently converted the epoxide to the diol and the microsomal epoxide inhibitor cyclohexene oxide inhibited quinoline-5,6-diol formation in rat liver microsomes. A preliminary kinetic analysis of quinoline metabolism in human liver microsomes was carried out and Eadie-Hofstee plots indicate that the formation of quinoline-5,6-diol is monophasic, while that of quinoline-1-oxide and 3-hydroxyquinoline is biphasic.
Introduction
Quinoline is a hepatocarcinogen in rats and mice, a wellknown mutagen in bacteria after incubation with rat liver microsomal fractions (1) and is capable of binding covalently to nucleic acids (2) . It is an industrial chemical, has been detected in cigarette smoke and can be formed in the body from tryptophan metabolism (3).
•Abbreviations: CYP, cytochrome P450; Q-l-oxide, quinoline-1-oxide; 3-OHQ, 3-hydroxyquinoline; mEH, microsomal epoxide hydrolase; Q-5,6-diol, quinoline-5,6-diol; Q-5,6-epoxide, quinoline-5,6-cpoxide; or, NADPH cytochrome P450 reductase; CHO, cyclohexene oxide; DDC, diethyldithiocarbamate.
To be mutagenic quinoline requires bioactivation by cytochrome P450 (CYP*) enzymes (3), as is the case for the majority of chemical carcinogens (4) , and we have determined the CYP enzymes responsible for quinoline metabolite formation in both human and rat liver microsomes. Our approach was multifaceted and used microsomes prepared from B lymphoblastoid cell lines expressing cDNAs encoding individual human and rat CYP enzymes, correlation of specific CYP-linked monooxygenase activities in different human liver microsomes with the formation of quinoline metabolites and inhibition of metabolite formation by specific chemicals and antibodies. In the course of this study we have observed possible differences in the metabolism of quinoline in human and rat liver microsomes.
Materials and methods

Materials
Quinoline, quinoline-1-oxide (Q-1-oxide) and 3-hydroxyquinoline (3-OHQ) were obtained from Nacalai Tesque (Tokyo, Japan). NADP + and glucose 6-phosphate were purchased from Sigma Chemical Co. (St Louis, MO) and glucose 6-phosphate dehydrogenase was obtained from the Oriental Yeast Co. (Tokyo, Japan). Microsomes prepared from the human B lymphoblastoid cell line AHH-1 expressing individual human and rat CYP enzymes and human microsomal epoxide hydrolase (mEH) (benzo[a]pyrene-4,5-oxide hydrolase activity, 150 pmol/min/mg protein) and the anti-human CYP2A6 monoclonal antibody were purchased from Gentest Corporation (Woburn, MA). The human liver microsome samples were from SRI International (Menlo Park, CA). Anti-rat CYP1A2 antibody was obtained from Daiichi Pure Chemicals Co. (Ibaraki, Japan).
Isolation of rat microsomes
Male Sprague-Dawley rats were injected i.p. with 3-methylcholanthrene dissolved in com oil (50 mg/kg body wt) as reported by Saeki et al. (5) . The rats were fasted for 18 h and were then killed by decapitation 48 h after injection and the liver was rapidly excised. The microsomal fraction was isolated as previously reported (5) and the CYP and protein contents were determined using standard methods (6, 7) .
Incubation of quinoline with cDNA-expressed, rat and human liver microsomes
In each case the incubation mixture (0.5 ml) contained the following, unless otherwise stated: 1 mg/ml microsomal protein, 1 mg/ml NADP + , 1 mg/ml glucose 6-phosphate, 0.4 U/ml glucose 6-phosphate dehydrogenase and 0.05 mM quinoline. NADP + , glucose 6-phosphate and quinoline (which was supplied as a liquid) were prepared in potassium phosphate buffer (0.1 M, pH 7.4), but in the case of the cDNA-expressed CYP2A6 Tris-HCl buffer (0.1 M, pH 7.4) was used as the activity of CYP2A6 is inhibited by phosphate. Incubation was at 37°C for 1-2 h, depending on the experiment and reactions were terminated by the addition of l/10th of the reaction volume of 10* trichloroacetic acid and centrifuged at 14 000 g to remove precipitated protein.
Supematants were passed through a 0.4 urn filter prior to injection onto the HPLC column.
HPLC
A Shimadzu model SPD-6A delivery system equipped with a TSK gel-ODS 80Tm column (4.6X150 mm) and a Waters model 99 U UV-vis photodiode array detector was used to analyze the reaction supematants. The flow rate was 1 ml/min and the solvent gradient program was as follows: 5% MeOH in 10 mM NaH 2 PO 4 for 5min followed by a linear gradient of MeOH to 40% over 15 min, 40% MeOH maintained for 10 min with a return to 5% MeOH over 5 min. A wavelength of 290 nm was used to detect quinoline and its metabolites. All assays contained 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM magnesium chloride and glucose-6-phosphate dehydrogenase at 0.4 U/ml except for 2E1 in which case 1 U/ml was used. 1A2: After addition of 0.5 ml 2% ZnSO 4 and centrifugation the supernatant was extracted with 5 ml dichloromethane:isopropanol (4:1). The organic phase was dried under nitrogen, resuspended in 0.15 ml and 0.1 ml was injected onto the column. 2A6: After addition of 0.1 ml 20% trichloroacetic acid and centrifugation, 0.1 ml of supernatant was added to 1.9 ml of 100 mM Tris pH 9 prior to measurement of fluorescence. 2B6: The incubation was diluted to 2 ml with 0.1 M Tris pH 9 prior to measurement of fluorescence. 2D6: After addition of 25 |il of 70% perchloric acid and centrifugation, 20 [l\ of supernatant was injected onto the column and separated at 50°C with a mobile phase of 30% acetonitrile, 1 mM perchloric acid at a flow rate of 1 ml/min. 2E1: After extraction with 0.75 ml dichloromethane and centrifugation, 0.5 ml of the organic phase was transferred to a rube and extracted again. The extracts were pooled, dried under nitrogen, resuspended in 0.1 ml acetonitrile:water (4:6), injected onto the column and separated at 50°C with a mobile phase of 30% acetonitrile, 2 mM perchloric acid at a flow rate of 1.2 ml/min. 3A4: After addition of 0.75 ml of ethylacetate and centrifugation the supernatant was further extracted with 0.5 ml of ethylacetate. The combined organic phases were dried and resuspended in 0.2 ml of methanol. After somcation 0.2 ml of water was added and 0.1 ml was loaded onto the column. 
Determination of monooxygenase-linked activities in human liver microsomes
The monooxygenase-linked activities were determined by a series of specific assays (Table I )-Assays contained cofactors as outlined above and protocols were carried out as detailed in the Gentest Corp. manual except for the following assays, which contained 10 mM NADPH. (i) 1A2. To stop the reaction 0.5 ml 2% ZnSO 4 was added and after centrifugation the supernatant was extracted with 5 ml dichloromethane:isopropanol (4:1). The organic phase was dried under nitrogen, re-suspended in 0.15 ml 0.1 M potassium phosphate (pH 4):acetonitrile (85:15) (mobile phase) and 0.1 ml was injected onto a 5(1 ODS 312A column and separated at a flow rate of 0.7 ml/min with detection at a wavelength of 245 nm.
(ii) 2E1. The reaction mixture was extracted with 0.75 ml dichloromethane and after centnfugation, 0.5 ml of the organic phase was transferred to a tube and re-extracted. The extracts were pooled, dried under nitrogen, re-suspended in 0.1 ml acetonitrile:water (4:6), injected onto a 5n Nucleosil C18 column and separated at 50°C with a mobile phase of 30% acetonitrile, 2 mM perchloric acid at a flow rate of 1.2 ml/min with detection at a wavelength of 280 nm. (iii) 3A4. The reaction mixture was extracted with 0.75 ml ethylacetate and after centrifugation the supernatant was further extracted with 0.5 ml ethylacetate. The combined organic phases were dried and re-suspended in 0.2 ml methanol. After sonication, 0.2 ml water was added and 0.1 ml was injected onto an Irika RP-18t column and separated with a mobile phase of 1 mM HCIO4CHCN3 at a flow rate of 1 ml/min with detection at a wavelength of 254 nm.
Results
Identification of metabolites
Using a UV-vis photodiode array detector attached to the HPLC column, metabolite peaks were identified by comparison of their UV spectra with UV spectra of the standard compounds in the case of Q-l-oxide and 3-OHQ and to published spectra (5) in the case of quinoline-5,6-diol (Q-5,6-diol) and quinoline-5,6-epoxide (Q-5,6-epoxide).
Comparison of quinoline metabolite profiles in human and rat liver microsomes
When human liver microsomes were incubated in the reaction assay with quinoline only a very small epoxide peak was detectable (even at 20 mM quinoline; results not shown) and a time course study (quinoline 0.05 mM; results not shown) over 120 min (time points 0, 5, 10, 15, 30, 60 and 120 min) revealed that the epoxide peak was only slightly detectable at any time point. In contrast, an epoxide peak was clearly detectable when quinoline was incubated with rat liver microsomes, indicating that the epoxide was stable under the assay conditions. Q-l-oxide, which was clearly detectable when quinoline was incubated with the human microsomes, was barely detectable when it was incubated with rat microsomes (results not shown). These results indicated differences in quinoline metabolism between rat and human microsomes which we investigated further.
Incubation of quinoline with Gentest microsomes (human)
Quinoline (0.05 mM) was incubated with microsomes prepared from a B lymphoblastoid cell line individually expressing human CYP1A1, 1A2, 2A6or, 2B6, 2C9or, 2D6, 2Elor and 3A4or (or; NADPH cytochrome P450 reductase) and with control microsomes from a cell line containing vector only and a cell line expressing only the reductase. Due to the commercial unavailability of standards of Q-5,6-diol and Q-5,6-epoxide the results outlined in Figure 1 were expressed in terms of metabolite peak area/min/pmol CYP. The results indicate that CYP2A6 is the principal CYP involved in the formation of Q-1-oxide and Q-5,6-epoxide and that CYP2E1 is the principal CYP involved in the formation of 3-OHQ. The results regarding Q-5,6-diol are more difficult to interpret as we have evidence to suggest that Q-5,6-diol is formed from Q-5,6-epoxide by mEH (see below).
Correlation of quinoline metabolite formation with specific CYP-linked activities in human liver microsomes
Specific CYP-linked monooxygenase activities in 11 human microsome samples (10 for Q-1-oxide) were correlated with quinoline metabolite formation. The correlations are shown in Figure 2 and Table II . Formation of Q-1-oxide was correlated with CYP2A6 activity (r = 0.95) and that of 3-OHQ was correlated with CYP2E1 activity (r = 0.93), in agreement with the results obtained using the cDNA-expressed isoforms. The formation of Q-5,6-diol correlated well with the activity of CYP2A6 (r = 0.91), but we feel that this correlation must reflect the involvement of CYP2A6 in the formation of Q-5,6- Table II for the correlation coefficients of all the monooxygenase-linked activities.
epoxide (from which the diol is formed), since we have shown that CYP2A6 cannot convert the epoxide to the diol ( Figure  3) . It was not possible, however, to correlate formation of the epoxide directly with any of the monooxygenase-linked activities in the human samples due to the small size of the Q-5,6-epoxide peak detectable when quinoline was incubated with human liver microsomes.
Formation of Q-5,6-diol by microsomal epoxide hydrolase
Approximately 0.8 mM Q-5,6-epoxide (containing some impurities), synthesized according to a previously described method (8), was incubated separately for 2 h with CYP2A6 and the cDNA-expressed human mEH and for 2 h in the absence of microsomal protein as a control. The results ( Figure  3) show that CYP2A6 was incapable of converting the epoxide to the diol. However, almost all of the epoxide was converted to the diol by human mEH, suggesting that this is the enzyme responsible for the conversion in human liver microsomes. In order to confirm this we sought to show inhibition of Q-5,6-diol formation by cyclohexene oxide (CHO), a specific inhibitor of mEH. In order to inhibit the formation of the diol, concentrations of CHO up to 5 mM had to be used and at these concentrations inhibition was non-specific ( Figure 4) . The same was found to be true of the competitive inhibitor styrene oxide. This is in marked contrast to the situation in rat liver microsomes, where formation of the diol was inhibited by much lower concentrations of CHO (see below). We did, however, observe inhibition of the cDNA-expressed human mEH with CHO (results not shown) which was similar to the inhibition observed in rat microsomes. While this result casts some doubt on the involvement of mEH in the conversion in human liver microsomes, mEH is, at this point, the best candidate for the enzyme which converts the epoxide to the diol. Unfortunately, due to the commercial unavailability of the highly specific mEH inhibitor 1,1,1-trichloropropene oxide, we were unable to examine the effect of this inhibitor on the conversion in human liver microsomes.
Inhibition of quinoline metabolism in human liver microsomes by specific antibodies and inhibitors
Quinoline metabolism was examined in the presence of: (i) a monoclonal antibody to human CYP2A6; (ii) furafylline, which is a highly specific inhibitor of human CYP1A2 (9); (iii) diethyldithiocarbamate (DDC), an inhibitor of CYP2E1 ( Figure  5 ). The results confirm that CYP2A6 is involved in the formation of Q-5,6-epoxide (using Q-5,6-diol as an indicator of epoxide formation) and Q-l-oxide, but the involvement of CYP1A2 in formation of the epoxide is also indicated, since formation of the diol (again used as an indicator of epoxide production) was inhibited by furafylline. Inhibition of 3-OHQ formation by DDC confirms that CYP2E1 is responsible for the formation of 3-OHQ. The apparent inhibition of 3-OHQ Reactions were carried out in duplicate and the quinoline concentration ranged from 0.005 to 20 mM. The plots for Q-l-oxide and 3-OHQ were solved for two components using Microsoft Excel.
formation by a monoclonal antibody to CYP2A6 can be explained by the fact that this antibody displays some crossreactivity to CYP2E1 and is weakly inhibitory towards CYP2E1 in the specific assay for this CYP activity (product information leaflet).
Kinetics of quinoline metabolism
We carried out a preliminary kinetic analysis of quinoline metabolism in human liver microsomes to establish whether metabolite formation was mono-or biphasic. Eadie-Hofstee plots for the formation of Q-5,6-diol, Q-l-oxide and 3-OHQ were constructed by incubating one of the human liver microsome samples with various concentrations of quinoline (0.005-20 mM) for 60 min, over which time the formation of metabolites was found to be linear (results not shown). The plots shown in Figure 6 suggest that the formation of Q-5,6-diol is monophasic, while that of Q-l-oxide and 3-OHQ is biphasic, indicating the involvement of both a high and low affinity component in the formation of these metabolites (see Discussion). The kinetic parameters for formation of the metabolites are outlined in Table IE . In the case of 3-OHQ, CYP2E1 appears to be the low affinity isoform involved in the formation of this metabolite, as the high affinity form has a very low V^ (0.03 nmol/min/mg), making its contribution insignificant at the concentration of quinoline used in the assays (0.05 mM).
Metabolism of quinoline by rat microsomes
Incubation of quinoline (0.05 mM) with microsomes prepared from a cell line expressing rat CYP2A1 (the orthologous form to human CYP2A6) showed that CYP2A1 was incapable of forming Q-l-oxide. Rat CYP2E1, however, formed 3-OHQ (~27 peak area units/min/pmol CYP) and Q-5,6-epoxide (~21 peak area units/min/pmol CYP). In rat liver microsomes formation of the diol was inhibited almost 90% (with a concomitant increase in epoxide formation; not shown on the graph) by the mEH inhibitor CHO at concentrations ranging from 0 to 0.4 mM (Figure 7 ), indicating that mEH is the enzyme responsible for conversion of the epoxide to the diol in the rat liver microsomes. Formation of Q-5,6-diol was inhibited by almost 90% by anti-rat CYP1A2 antibody (Figure 8 ), indicating that CYP1A2 (or CYP1A1, since the antibody equally inhibits CYP1A1 activity) is responsible for production of the epoxide in the rat microsomes. In this experiment formation of the diol was again used as an indicator of epoxide production, as the control serum (pre-immune serum) used in the reaction resulted in the disappearance of the epoxide peak. Inhibition of quinoline metabolism by DDC resulted in inhibition of 3-OHQ formation, but no inhibition of Q-5,6-diol formation, indicating that CYP2E1 is not involved in formation of the epoxide in rat liver microsomes even though it is capable of epoxide formation. Thus the postulated metabolism of quinoline in human and rat liver microsomes is outlined in Figure 9 .
Discussion
The present study was undertaken to establish the CYP isoforms involved in formation of quinoline metabolites in both human and rat microsomes. Results from incubation with human cDNA-expressed CYPs (Figure 1 ) indicate that CYP2A6 is the principal isoform responsible for formation of Q-l-oxide and Q-5,6-epoxide and that CYP2E1 is the principal CYP involved in formation of 3-OHQ in humans. In the case of Q-5,6-diol, although it appears from the results that CYP2A6 is the principal CYP involved in formation, we have shown that CYP2A6 is incapable of forming the diol when incubated with Q-5,6-epoxide (Figure 3 not involved in formation of the diol. Only very small quantities of Q-5,6-diol were formed when quinoline was incubated with the cDNA-expressed human enzymes (a maximum of ~2 peak area units/min/pmol CYP for the diol as opposed to a maximum of 8-20 peak area units/min/pmol CYP for the other metabolites) and this may indicate formation of the diol by mEH present in the AHH-1 cell line at undetectable levels or some spontaneous formation of the diol from the epoxide. We have demonstrated that human mEH can convert Q-5,6-epoxide to the diol, indicating that this may be the enzyme involved in the conversion in human liver microsomes (Figure 3) . Results obtained in the correlation studies confirmed the involvement of CYP2A6 in the formation of Q-l-oxide {r = 0.95) and CYP2E1 in the formation of 3-OHQ (r = 0.93). The formation of Q-5,6-diol correlated with the activity of CYP2A6 (r = 0.91), reflecting the involvement of CYP2A6 in formation of the epoxide and indicating that the second, presumably mEHcatalyzed, step in the reaction from quinoline to the diol is not rate limiting. When a monoclonal antibody to CYP2A6 was pre-incubated with the human microsomes prior to their use in the quinoline metabolism assay the involvement of CYP2A6 in the formation of both Q-l-oxide and Q-5,6-epoxide was confirmed. Use of the specific CYP1A2 inhibitor furafylline, however, also resulted in inhibition of Q-5,6-diol formation, indicating the involvement of CYP1A2 in formation of the epoxide. When quinoline was incubated with individual human CYPs (Figure 1 ), CYP1A2 was observed to be capable of forming the epoxide at about half the activity of CYP2A6.
We observed ~80% inhibition of 3-OHQ formation when DDC was pre-incubated with quinoline and human liver microsomes in our assay. We used DDC at low concentrations (0-10 |iM) and we observed no significant inhibition of formation of the diol or oxide, thus confirming that CYP2E1 is responsible for the formation of 3-OHQ. The results from the kinetic analysis of quinoline metabolism ( Figure 6 ) indicate that Q-5,6-diol formation is monophasic, which agrees well with the assumption that the diol is formed by mEH. Both Q-1-oxide and 3-OHQ formation is biphasic and we have some preliminary evidence based on furafylline inhibition of 3-OHQ formation in some human liver microsome samples to suggest that CYP1A2 is actually the high affinity isoform involved in the formation of 3-OHQ. A similar situation has been observed in the metabolism of chlorzoxazone by human CYP2E1 and CYP1A2 (10), where the K m values of CYP1A2 and CYP2E1 for the reaction were 5.69 and 232 |iM respectively, while the max value of CYP2E1 for the reaction was ~8.5 times higher than that of CYP1A2 and a good correlation was obtained between the amount of human CYP2E1 protein in microsomal samples and chlorazoxazone 6-hydroxylase activity at the concentration of substrate used. In our reaction the V,^ of the low affinity isoform was ~19 times higher than that of the high affinity isoform and we have determined that the contribution of the high affinity isoform to the formation of 3-OHQ was insignificant at the concentration of quinoline used. However, if CYP1A2 is the high affinity isoform involved in the formation of 3-OHQ it would be expected to make a far greater contribution to 3-OHQ formation at lower quinoline concentrations and possibly have a much more significant role in vivo. In the case of Q-l-oxide we believe that CYP3A4 is the strongest candidate for the low affinity form, as this CYP was the principal isoform involved in the formation of Q-loxide on incubation of a higher concentration of quinoline (0.8 mM) with cDNA-expressed CYPs (results not shown).
The difference in inhibition of quinoline metabolism by CHO in rat and human liver microsomes suggests that a species difference exists between the human and rat mEH enzymes if, as seems likely, mEH is responsible for formation of the diol in liver microsomes. Such a difference has been reported by various authors, documented in the review article by Lu and Miwa (11). However, we observed inhibition of the cDNA-expressed human mEH enzyme by CHO (results not shown), suggesting that inhibition by CHO is not subject to this species difference. It has been reported that CHO exerts differential inhibition on the hydration of different substrates when either purified rat enzyme or rat liver microsomes are used (12) and it is possible therefore that in this study we have observed the same phenomenon regarding CHO inhibition of diol formation in human liver microsomes and in microsomes containing only the human cDNA-expressed form.
In this study we observed that Q-l-oxide was formed in barely detectable quantities when quinoline was incubated with rat liver microsomes. We have determined that in human liver microsomes Q-l-oxide is formed by CYP2A6, an isoform which is present in neglible quantities or is absent in rat microsomes (13) , and we have observed that rat CYP2A1 (the orthologous form to human CYP2A6) is incapable of forming the oxide. Human liver was found to contain constitutive coumarin hydroxylase activity (mediated by CYP2A6) of up to 500 pmol/mg microsomal protein/min, whereas the activity in rat liver microsomes was 3-5 pmol/mg/min and could only be determined with high substrate concentrations (13) . Other authors have reported Q-l-oxide formation on incubation of quinoline with rat liver microsomes (5, 14) , but in each case the concentration of quinoline used in the assays was 5-10 times the concentration of quinoline used in this study. When the rats were pretreated with 3-methylcholanthrene (5,14) (as in our study) Q-l-oxide formation represented only 3-5% of total metabolite formation even at the higher concentrations of quinoline. However, when the rats were pre-treated with phenobarbital (14) the principal metabolite was Q-l-oxide (36.9% of total metabolite formation). This is most likely due to Q-l-oxide formation by CYP3A2, the orthologous form to human CYP3A4, as we have observed that CYP3A4 is capable of forming Q-1-oxide at higher quinoline concentrations and phenobarbital is known to be an inducer of rat CYP3A2 (15) . That Q-1-oxide formation is dependant upon the inducer used to pre-treat the rats (14) strongly suggests that the oxide is formed by CYP-linked monooxygenases. While the formation of N-O bonds is often catalyzed by flavin monooxygenase, it has been reported that CYPs can also catalyze such reactions (16) .
Inhibition studies with an anti-rat CYP1A2 antibody (which equally inhibits CYP1A1) and DDC indicated that in rat liver microsomes CYP1A2 or CYP1A1 is responsible for the formation of Q-5,6-epoxide and that CYP2E1 is involved in the formation of 3-OHQ. Tada etal. (14) reported that CYP1A2 is responsible for formation of the epoxide in rat microsomes.
CYP2E1 has been shown to be involved in the formation of 3-OHQ in both human and rat liver microsomes and this may have implications for the mutagenicity of quinoline, since it has been suggested recently that mutagenic activation takes place in the pyridine moiety (5, 17) . CYP2E1 has also been shown to be the major, if not the principal, catalyst of the oxidation of a range of other potential carcinogens, including benzene, styrene, CC1 4 , CHC1 3 , CH 2 C1 2 , 1,2-dichloropropane, ethylene dichloride, vinyl chloride and ethyl carbamate (18) .
Since, in this study, the comparison between quinoline metabolism in human and rat microsomes was based upon results obtained using only microsomes prepared from 3-MCtreated male rats, these results indicate possible rather than unequivocal species differences in quinoline metabolism. Nevertheless, we feel that our study highlights the problem of extrapolating results from the rat to the human and supports the contention that in this type of study, particularly where the compound under investigation is a drug or drug candidate, it is advisable to use human microsomes and enzymes.
